VEGFA and age-related macular degeneration: A significant proportion of ophthalmic procedures in the National Health Service (NHS) are related to the treatment of AMD, specifically the administration of intravitreal anti-vascular endothelial growth factor (VEGF) injections every 4–8 weeks for managing the neovascular/end-stage form of the disease.